August 8, 2011
HUYA Bioscience International and Shanghai Jiao Tong University King’s Lab Form Alliance
SAN DIEGO, Aug. 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.
The agreement provides HUYA with access to and first review of certain novel therapeutic candidates owned or controlled by King's Lab. Correspondingly, King's Lab gains access to HUYA's expertise in drug development as well as its global network of pharmaceutical partners.HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.
Shanghai Jiao Tong University School of Pharmacy King's Lab is a research laboratory situated at Shanghai Jiao Tong University's Minhang campus. The university boasts a large number of renowned professors and scientists. The School of Pharmacy is one of the youngest but fastest growing pharmacy schools in China. The King's Lab has been built for discovery and preclinical development of novel medicines for unmet medical needs. It is in collaboration with many leading domestic and international bio-pharmaceutical companies.
"Shanghai Jiao Tong University School of Pharmacy differs from many traditional pharmacy schools in China by having systematic research and educational programs to investigate emerging therapeutic areas," said Clement Gingras, HUYA's CTO and COO, China. "HUYA and Shanghai Jiao Tong University School of Pharmacy King's Lab mutually aspire to become the forefront of China's push for creating a competitive bioscience industry with pharmaceutical innovations."
Dr Yong X. Wang, Head of Shanghai Jiao Tong University School of Pharmacy King's Lab, commented, "Our goal is to become a leading center for pharmaceutical innovation, with HUYA's knowledge in developing China's innovative drug candidates. We have recently discovered several new target molecules and novel leads for chronic pain."
ABOUT HUYA BIOSCIENCE INTERNATIONAL
HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com
ABOUT SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF PHARMACY KING'S LAB
Established in 2003, King's Lab is located in the Minhang campus of Shanghai Jiao Tong University, Shanghai, China. With a total area of more than 200 square meters, the King's Lab is well equipped with advanced laboratory equipment including cell cultivation and experimental animal rooms. Its research focuses on Translational Pharmacology in the areas of pain including neuropathic pain and cancer pain, metabolic diseases including diabetes and obesity, and cancers, as well as DNA methylation gene silencing technology and PEGylation technology, funded by grants from National Natural Science Foundation of China, National High-Tech "863" Program and the Mega New Drug Development Program of China. King's Lab has published many peer-reviewed scientific papers in reputed journals such as Science, Pain, British Journal of Pharmacology (BJP) and Journal of Pharmacology and Experimental Therapeutics (JPET). For more information, please visit www.pharm.sjtu.edu.cn/engpharmacy/research/wangyongxiang.html
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
SOURCE HUYA Bioscience International